PYR-002

PYR-002 is an early-stage investigational drug candidate developed by Pyros Pharmaceuticals, which is now a subsidiary of Upsher-Smith. The drug is part of a pipeline dedicated to addressing unmet needs in rare pediatric diseases, particularly within the neurodevelopmental and orphan disease space. As of early 2024, specific details regarding its molecular target, mechanism of action, and primary therapeutic indication remain proprietary and have not been publicly disclosed. The candidate is currently in the preclinical or early development phase, following the company's focus on enhancing therapies for conditions such as infantile spasms.